April 14, 2021

Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• Adults with COVID-19 who were not hospitalized and received the monoclonal antibody therapy bamlanivimab (n = 218) had a 63% lower 30-day hospitalization rate than those who did not receive the treatment (n = 185) in a case-control study conducted between November 20, 2020 and January 19, 2021. Odds of hospitalization was 4.2 times higher among controls who had a referral order but did not receive bamlanivimab than those who received treatment. To prevent one hospitalization, 8 patients with mild or moderate COVID-19 would need to be treated with bamlanivimab.

Kumar et al. (Apr 13, 2021). Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab305